Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $70.00 price target on the stock.
Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? [Yahoo! Finance]
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success [Yahoo! Finance]
J&J and Protagonist's icotrokinra scores in Phase IIb UC study [Yahoo! Finance]
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "outperform" rating re-affirmed by analysts at Wedbush.